Evaluation of MADIT II risk stratification score among registry of heart failure patients with primary prevention ICD/CRTD device
Abstract Funding Acknowledgements Type of funding sources: None. Background Current guidelines advocate primary prevention ICD implantation for all symptomatic heart failure (HF) patients with low LVEF. As most patients will not use their device during lifetime, a score delineating subgroups with di...
Gespeichert in:
Veröffentlicht in: | Europace (London, England) England), 2023-05, Vol.25 (Supplement_1) |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Current guidelines advocate primary prevention ICD implantation for all symptomatic heart failure (HF) patients with low LVEF. As most patients will not use their device during lifetime, a score delineating subgroups with differential ICD benefit is crucial. The MADIT Risk Stratification Score (MRSS) based on 5 parameters including: age>70, Creatinine >1.4 mg/dl, QRS width >120ms, presence of AF, and NYHA >2, was developed for this purpose.
Objective
Evaluate MRSS among Israeli nationwide registry of HF patients implanted with prophylactic ICD/CRTD. Endpoints included overall mortality, sustained ventricular arrhythmia (VA), and competing risk of arrhythmic (VA-related) versus non-arrhythmic death, a surrogate for potential ICD survival benefit.
Methods
Study based on comprehensive registry of ICD/CRTDs implanted in Israel between 2011-2018. All registry patients were categorized into MRSS-based risk-groups (low-risk- MRSS 0, intermediate-risk- MRSS 1-5, very high-risk (VHR) group defined by Creatinine >2.5mg/dL). Univariate and Kaplan Meier analysis used to evaluate the association of risk groups with study endpoints.
Results
2177 HF patients, implanted with a primary prevention ICD (1255, 58%) or CRTD (922, 42%) were included. There were 189 (8.7%) patients with sustained VA and 316 (14.5%) deaths during median follow-up (F/U) period of 2.5 years. A significant correlation was found between MRSS-based risk subgroups and overall mortality (p 0.001). However, MRSS association with sustained VA was weak (p 0.2). Notably, the MRSS-based very high-risk (VHR) subgroup had an exceptionally high mortality but low VA incidence. Competing risk of arrhythmic versus non-arrhythmic death revealed a large and significant ICD survival benefit among the low and intermediate MRSS-based risk subgroups, with 10.2 and 12.3 months survival gained over 3-year F/U period among these subgroups, respectively (p 0.001). The VHR subgroup in contrast, showed a minimal non-significant ICD survival benefit.
Conclusions
Use of MRSS among a contemporary real-world registry of HF patients revealed subgroups with differing ICD survival benefit, suggesting it as a universal tool to predict ICD survival benefit. MRSS-based VHR subgroup may not gain survival benefit from prophylactic ICD implant. |
---|---|
ISSN: | 1099-5129 1532-2092 |
DOI: | 10.1093/europace/euad122.431 |